State Street Corp Vaxxinity, Inc. Transaction History

State Street Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.7 - $1.31 $23,240 - $43,492	-33,200 Reduced 3.99%	799,273 $679,000
Q3 2023 Nov 14, 2023	BUY	$1.25 - $3.0 $70,712 - $169,710	56,570 Added 7.29%	832,473 $1.14 Million
Q2 2023 Aug 14, 2023	BUY	$1.73 - $2.79 $1.13 Million - $1.83 Million	654,969 Added 541.59%	775,903 $1.96 Million
Q1 2023 May 15, 2023	BUY	$1.43 - $4.24 $94,666 - $280,688	66,200 Added 120.95%	120,934 $274,000
Q4 2022 Feb 14, 2023	BUY	$1.31 - $2.62 $71,701 - $143,403	54,734 New	54,734 $76,000

198K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.